A Phase 1, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Immunogenicity, and Pharmacodynamics Following Intravenous Dose of PF-07264660 in Chinese Healthy Adult Participants
Latest Information Update: 09 Jul 2025
At a glance
- Drugs PF 07264660 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 01 Jul 2025 Planned End Date changed from 31 Aug 2025 to 28 Aug 2025.
- 01 Jul 2025 Planned primary completion date changed from 31 Aug 2025 to 28 Aug 2025.
- 20 Apr 2025 Planned End Date changed from 30 Sep 2025 to 31 Aug 2025.